1.Research progress on the value of splenomegaly in the diagnosis and treatment of biliary atresia
Xingyuan KE ; Jiaying LIU ; Yanran ZHANG ; Tengfei LI ; Jianghua ZHAN
Chinese Journal of Hepatobiliary Surgery 2025;31(11):867-871
Biliary atresia is often complicated with portal hypertension, which induces a series of hemodynamic changes leading to splenomegaly. Splenomegaly is a common in patients with biliary atresia, which indicates the status of portal hypertension, esophageal varices, and the progression of hepatic fibrosis. Furthermore, it can help monitor the native liver survival status after Kasai procedure and the need for liver transplantation. For patients with biliary atresia presenting splenomegaly and/or hypersplenism, the treatment strategy, involving the pharmacological or surgical options, should be individually selected based on specific clinical condition. This article reviews the value of splenomegaly in the diagnosis and management of biliary atresia, aiming to provide references for clinical practice.
2.Research progress of fat-soluble vitamin deficiency and its prevention in children with biliary atresia
Qi JI ; Qianhui YANG ; Yanran ZHANG ; Shaowen LIU ; Jianghua ZHAN
Chinese Journal of Hepatobiliary Surgery 2025;31(3):236-240
Biliary atresia is a progressive disease involving the intrahepatic and extrahepatic bile ducts. At present, the widely used treatment strategy is portojejunostomy (Kasai procedure). However, fat-soluble vitamin deficiency is common in children with biliary atresia, leading to growth retardation and malnutrition, which further affects the therapeutic effect prognosis of children. This article reviews the etiology, performance, prevention and treatment of fat-soluble vitamins deficiency in children with biliary atresia.
3.Research progress on the value of splenomegaly in the diagnosis and treatment of biliary atresia
Xingyuan KE ; Jiaying LIU ; Yanran ZHANG ; Tengfei LI ; Jianghua ZHAN
Chinese Journal of Hepatobiliary Surgery 2025;31(11):867-871
Biliary atresia is often complicated with portal hypertension, which induces a series of hemodynamic changes leading to splenomegaly. Splenomegaly is a common in patients with biliary atresia, which indicates the status of portal hypertension, esophageal varices, and the progression of hepatic fibrosis. Furthermore, it can help monitor the native liver survival status after Kasai procedure and the need for liver transplantation. For patients with biliary atresia presenting splenomegaly and/or hypersplenism, the treatment strategy, involving the pharmacological or surgical options, should be individually selected based on specific clinical condition. This article reviews the value of splenomegaly in the diagnosis and management of biliary atresia, aiming to provide references for clinical practice.
4.Research progress of fat-soluble vitamin deficiency and its prevention in children with biliary atresia
Qi JI ; Qianhui YANG ; Yanran ZHANG ; Shaowen LIU ; Jianghua ZHAN
Chinese Journal of Hepatobiliary Surgery 2025;31(3):236-240
Biliary atresia is a progressive disease involving the intrahepatic and extrahepatic bile ducts. At present, the widely used treatment strategy is portojejunostomy (Kasai procedure). However, fat-soluble vitamin deficiency is common in children with biliary atresia, leading to growth retardation and malnutrition, which further affects the therapeutic effect prognosis of children. This article reviews the etiology, performance, prevention and treatment of fat-soluble vitamins deficiency in children with biliary atresia.
5.Exploration of the Mechanism of Icariin on Prostate Cancer Based on Network Pharmacology and Animal Experiments
Wenli LIN ; Yanran ZHAN ; Yanfen CHEN ; Jiahui HE ; Yuanjun WEI ; Taofen CHEN ; Xiangtao WENG ; Chiming GU
Herald of Medicine 2024;43(12):1874-1880
Objective To investigate the intervention effects and mechanism of icariin on prostate cancer based on network pharmacology and animal experiments.Methods The targets of icariin were predicted using the SwissTargetPrediction database.Protein-protein interaction networks were constructed with the String database,and core targets were screened using Cytoscape 3.9.1.GO and KEGG enrichment analysis on core targets were conducted with the Metascape database to predict the mechanism of action.A PC-3 tumor-bearing mouse model of prostate cancer was established to observe the inhibitory effects of icariin alone and in combination with paclitaxel on tumor growth.Results Network pharmacology predictions suggested that icariin has potential therapeutic effects on prostate cancer,with core targets potentially including serine/threonine kinase 1(AKT1),B-cell lymphoma-2(BCL2),epidermal growth factor receptor(EGFR),heat shock protein 90 alpha family class A member 1(HSP90AA1),heat shock protein 90 alpha family class B member 1(HSP90AB1),nuclear factor kappa B subunit 1(NF-κB1),tumor protein p53,etc.Animal experiments found that compared with the model control group,the tumor volume growth in the icariin group and the paclitaxel group was significantly inhibited,and the serum tumor necrosis factor content was significantly reduced,while testosterone levels did not change significantly.Both groups significantly downregulated the mRNA expression of Notch1,Jagged1 and Hes1(P<0.05),with the combined treatment group showing a more significant inhibitory effect.Conclusions Both network pharmacology and animal experimental results confirmed that icariin has a significant inhibitory effect on prostate cancer.One of the mechanisms of its anti-tumor effects may be the significant inhibition of the activated Notch signaling pathway in tumors.

Result Analysis
Print
Save
E-mail